TY - JOUR
T1 - Diagnosis and management of AML in adults
T2 - 2017 ELN recommendations from an international expert panel
AU - Döhner, Hartmut
AU - Estey, Elihu
AU - Grimwade, David
AU - Amadori, Sergio
AU - Appelbaum, Frederick R.
AU - Büchner, Thomas
AU - Dombret, Hervé
AU - Ebert, Benjamin L.
AU - Fenaux, Pierre
AU - Larson, Richard A.
AU - Levine, Ross L.
AU - Lo-Coco, Francesco
AU - Naoe, Tomoki
AU - Niederwieser, Dietger
AU - Ossenkoppele, Gert J.
AU - Sanz, Miguel
AU - Sierra, Jorge
AU - Tallman, Martin S.
AU - Tien, Hwei Fang
AU - Wei, Andrew H.
AU - Löwenberg, Bob
AU - Bloomfield, Clara D.
N1 - Publisher Copyright:
© 2017 by The American Society of Hematology.
PY - 2017/1/26
Y1 - 2017/1/26
N2 - The first edition of the European Leuke-miaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.
AB - The first edition of the European Leuke-miaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.
UR - http://www.scopus.com/inward/record.url?scp=85014879329&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014879329&partnerID=8YFLogxK
U2 - 10.1182/blood-2016-08-733196
DO - 10.1182/blood-2016-08-733196
M3 - Review article
C2 - 27895058
AN - SCOPUS:85014879329
SN - 0006-4971
VL - 129
SP - 424
EP - 447
JO - Blood
JF - Blood
IS - 4
ER -